Deals


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">BMS sees potential first-in-class therapy in deal for Agenus&#x2019; bispecific TIGIT-targeting mAb</h1><h2 class="title-bottom webtitle" doc-editable="title" data-component-id="doc-1ef7l34r60"></h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Paul Bonanos, Associate Editor</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


Agenus Inc.

Bristol Myers Squibb Co.

AGEN1777

T cell immunoreceptor with Ig and ITIM domains (TIGIT)

BMS sees potential first-in-class therapy in deal for Agenus’ bispecific TIGIT-targeting mAb

BMS’s belief that Agenus has built a differentiated TIGIT-targeting bispecific molecule has resulted in a potentially transformative deal for the biotech, delivering $200 million up front for

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

The BioCentury Show

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><br/><center><span style="font-size:1.75rem;font-weight:500;">Access this Article</span></center>